DLBCL

Oncology·MeSH: Lymphoma, Large B-Cell, Diffuse

Prevalence

30.0 / 100K

35 drugs in development·20 companies·6 clinical trials

Drug Pipeline by Phase

Approved(3)

Drug	Company
clonoSEQ	Adaptive Biotechnologies Corp (ADPT)
Monjuvi	Xencor Inc (XNCR)
xpovio	Karyopharm Therapeutics Inc. (KPTI)

Phase 3(9)

Drug	Company
Bendamustine	Merck & Co., Inc. (MRK)
CHOP	Filana Therapeutics Inc. (FLNA)
Granulocyte Colony-Stimulating Factor	Merck & Co., Inc. (MRK)
kte-c19	Kite Pharma, Inc. (KITE)
liso-cel	CELGENE CORP /DE/ (CELG)
obinutuzumab	GH Research PLC (GHRS)
R-CHOP	Filana Therapeutics Inc. (FLNA)
vincristine	REGENERON PHARMACEUTICALS, INC. (REGN)
Zilovertamab vedotin	Merck & Co., Inc. (MRK)

Phase 2(7)

Drug	Company
anti-cd20 car-t	CELLULAR BIOMEDICINE GROUP, INC. (CMBG)
bendamustine	CELLULAR BIOMEDICINE GROUP, INC. (CMBG)
CX-2029	CytomX Therapeutics, Inc. (CTMX)
cyt-0851	Cyteir Therapeutics, Inc. (CYT)
fs118	F-star Therapeutics, Inc. (FSTX)
Mivavotinib (CB-659, formerly TAK-659)	Calithera Biosciences, Inc. (CALA)
Mivavotinib (CB-659)	Calithera Biosciences, Inc. (CALA)

Phase 1(13)

Drug	Company
Chidamide	ENANTA PHARMACEUTICALS INC (ENTA)
E7777 (LYMPHIR) prior to CAR-T	CITIUS ONCOLOGY, INC. (CTOR)
fludarabine	CELLULAR BIOMEDICINE GROUP, INC. (CMBG)
Lisaftoclax	Filana Therapeutics Inc. (FLNA)
Lisaftoclax	Merus N.V. (MRUS)
LYMPHIR (investigator-initiated: pre-CAR-T)	CITIUS ONCOLOGY, INC. (CTOR)
odronextamab	REGENERON PHARMACEUTICALS, INC. (REGN)
POLA-R-CHP	Filana Therapeutics Inc. (FLNA)
POLA-R-CHP	Merus N.V. (MRUS)
Polatuzumab Vedotin	ENANTA PHARMACEUTICALS INC (ENTA)
R-CHOP	Merus N.V. (MRUS)
zamtocabtagene autoleucel	CELLULAR BIOMEDICINE GROUP, INC. (CMBG)
zelebrudomide	Nurix Therapeutics, Inc. (NRIX)

Phase 1/Phase 2(2)

Drug	Company
abexinostat	XYNOMIC PHARMACEUTICALS HOLDINGS, INC. (BCACU)
Fimepinostat	CURIS INC (CRIS)

Phase 4(1)

Drug	Company
Brentuximab Vedotin	ENANTA PHARMACEUTICALS INC (ENTA)

BioSniper tracks 35 drugs in development for DLBCL across 20 companies.

There are 6 clinical trials targeting DLBCL tracked by BioSniper.

The estimated prevalence of DLBCL is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.